Cargando…
When Does the IC(50) Accurately Assess the Blocking Potency of a Drug?
[Image: see text] Preclinical assessment of drug-induced proarrhythmicity is typically evaluated by the potency of the drug to block the potassium human ether-à-go-go-related gene (hERG) channels, which is currently quantified by the IC(50). However, channel block depends on the experimental conditi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357848/ https://www.ncbi.nlm.nih.gov/pubmed/32105478 http://dx.doi.org/10.1021/acs.jcim.9b01085 |
_version_ | 1783558746477166592 |
---|---|
author | Gomis-Tena, Julio Brown, Brandon M. Cano, Jordi Trenor, Beatriz Yang, Pei-Chi Saiz, Javier Clancy, Colleen E. Romero, Lucia |
author_facet | Gomis-Tena, Julio Brown, Brandon M. Cano, Jordi Trenor, Beatriz Yang, Pei-Chi Saiz, Javier Clancy, Colleen E. Romero, Lucia |
author_sort | Gomis-Tena, Julio |
collection | PubMed |
description | [Image: see text] Preclinical assessment of drug-induced proarrhythmicity is typically evaluated by the potency of the drug to block the potassium human ether-à-go-go-related gene (hERG) channels, which is currently quantified by the IC(50). However, channel block depends on the experimental conditions. Our aim is to improve the evaluation of the blocking potency of drugs by designing experimental stimulation protocols to measure the IC(50) that will help to decide whether the IC(50) is representative enough. We used the state-of-the-art mathematical models of the cardiac electrophysiological activity to design three stimulation protocols that enhance the differences in the probabilities to occupy a certain conformational state of the channel and, therefore, the potential differences in the blocking effects of a compound. We simulated an extensive set of 144 in silico I(Kr) blockers with different kinetics and affinities to conformational states of the channel and we also experimentally validated our key predictions. Our results show that the IC(50) protocol dependency relied on the tested compounds. Some of them showed no differences or small differences on the IC(50) value, which suggests that the IC(50) could be a good indicator of the blocking potency in these cases. However, others provided highly protocol dependent IC(50) values, which could differ by even 2 orders of magnitude. Moreover, the protocols yielding the maximum IC(50) and minimum IC(50) depended on the drug, which complicates the definition of a “standard” protocol to minimize the influence of the stimulation protocol on the IC(50) measurement in safety pharmacology. As a conclusion, we propose the adoption of our three-protocol IC(50) assay to estimate the potency to block hERG in vitro. If the IC(50) values obtained for a compound are similar, then the IC(50) could be used as an indicator of its blocking potency, otherwise kinetics and state-dependent binding properties should be accounted. |
format | Online Article Text |
id | pubmed-7357848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-73578482020-07-14 When Does the IC(50) Accurately Assess the Blocking Potency of a Drug? Gomis-Tena, Julio Brown, Brandon M. Cano, Jordi Trenor, Beatriz Yang, Pei-Chi Saiz, Javier Clancy, Colleen E. Romero, Lucia J Chem Inf Model [Image: see text] Preclinical assessment of drug-induced proarrhythmicity is typically evaluated by the potency of the drug to block the potassium human ether-à-go-go-related gene (hERG) channels, which is currently quantified by the IC(50). However, channel block depends on the experimental conditions. Our aim is to improve the evaluation of the blocking potency of drugs by designing experimental stimulation protocols to measure the IC(50) that will help to decide whether the IC(50) is representative enough. We used the state-of-the-art mathematical models of the cardiac electrophysiological activity to design three stimulation protocols that enhance the differences in the probabilities to occupy a certain conformational state of the channel and, therefore, the potential differences in the blocking effects of a compound. We simulated an extensive set of 144 in silico I(Kr) blockers with different kinetics and affinities to conformational states of the channel and we also experimentally validated our key predictions. Our results show that the IC(50) protocol dependency relied on the tested compounds. Some of them showed no differences or small differences on the IC(50) value, which suggests that the IC(50) could be a good indicator of the blocking potency in these cases. However, others provided highly protocol dependent IC(50) values, which could differ by even 2 orders of magnitude. Moreover, the protocols yielding the maximum IC(50) and minimum IC(50) depended on the drug, which complicates the definition of a “standard” protocol to minimize the influence of the stimulation protocol on the IC(50) measurement in safety pharmacology. As a conclusion, we propose the adoption of our three-protocol IC(50) assay to estimate the potency to block hERG in vitro. If the IC(50) values obtained for a compound are similar, then the IC(50) could be used as an indicator of its blocking potency, otherwise kinetics and state-dependent binding properties should be accounted. American Chemical Society 2020-02-27 2020-03-23 /pmc/articles/PMC7357848/ /pubmed/32105478 http://dx.doi.org/10.1021/acs.jcim.9b01085 Text en Copyright © 2020 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes. |
spellingShingle | Gomis-Tena, Julio Brown, Brandon M. Cano, Jordi Trenor, Beatriz Yang, Pei-Chi Saiz, Javier Clancy, Colleen E. Romero, Lucia When Does the IC(50) Accurately Assess the Blocking Potency of a Drug? |
title | When Does the IC(50) Accurately Assess the
Blocking Potency of a Drug? |
title_full | When Does the IC(50) Accurately Assess the
Blocking Potency of a Drug? |
title_fullStr | When Does the IC(50) Accurately Assess the
Blocking Potency of a Drug? |
title_full_unstemmed | When Does the IC(50) Accurately Assess the
Blocking Potency of a Drug? |
title_short | When Does the IC(50) Accurately Assess the
Blocking Potency of a Drug? |
title_sort | when does the ic(50) accurately assess the
blocking potency of a drug? |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357848/ https://www.ncbi.nlm.nih.gov/pubmed/32105478 http://dx.doi.org/10.1021/acs.jcim.9b01085 |
work_keys_str_mv | AT gomistenajulio whendoestheic50accuratelyassesstheblockingpotencyofadrug AT brownbrandonm whendoestheic50accuratelyassesstheblockingpotencyofadrug AT canojordi whendoestheic50accuratelyassesstheblockingpotencyofadrug AT trenorbeatriz whendoestheic50accuratelyassesstheblockingpotencyofadrug AT yangpeichi whendoestheic50accuratelyassesstheblockingpotencyofadrug AT saizjavier whendoestheic50accuratelyassesstheblockingpotencyofadrug AT clancycolleene whendoestheic50accuratelyassesstheblockingpotencyofadrug AT romerolucia whendoestheic50accuratelyassesstheblockingpotencyofadrug |